Findings

What do systematic reviews say?

4,919 questions · 13,869 findings · 2,177 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Medically assisted hydration vs usual care

Quality of life · adults aged 18 years and older receiving palliative care

The review found no eligible studies for this question.

1 finding from 1 review

Medically assisted hydration for adults receiving palliative care 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Botulinum toxin vs surgery

Serious adverse events at 6 or 12 months · adults and children with strabismus

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin for the treatment of strabismus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Botulinum toxin vs surgery

Quality of life (validated questionnaire) · adults and children with strabismus

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin for the treatment of strabismus 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 2: PLD alone vs other conventional chemotherapy

Quality of life · recurrent platinum‐resistant EOC

The review found no eligible studies for this question.

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 1: PLD with chemotherapy vs PLD alone

Quality of life · recurrent platinum‐resistant EOC

The review found no eligible studies for this question.

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Death · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

End‐of‐treatment response · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Treatment discontinuation · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

Serious adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard interferon plus ribavirin vs standard interferon

Death · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard interferon plus ribavirin vs standard interferon

Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard interferon plus ribavirin vs standard interferon

End‐of‐treatment response · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard interferon plus ribavirin vs standard interferon

Sustained virological response · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard interferon plus ribavirin vs standard interferon

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegylated interferon plus ribavirin vs pegylated interferon alone

Death · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

Death · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

Relapse · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

Sustained virological response · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

Treatment discontinuation · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found